KANE, John L., Jr.,MATTHEWS, Gloria,METZ, Markus,KOTHE, Michael,LIU, Jinyu,SCHOLTE, Andrew
申请号：
HK17105905.4
公开号：
HK1232225A
申请日:
2017.06.14
申请国别(地区):
HK
年份:
2018
代理人:
摘要：
Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
